CA2893973A1 - Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii - Google Patents
Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii Download PDFInfo
- Publication number
- CA2893973A1 CA2893973A1 CA2893973A CA2893973A CA2893973A1 CA 2893973 A1 CA2893973 A1 CA 2893973A1 CA 2893973 A CA2893973 A CA 2893973A CA 2893973 A CA2893973 A CA 2893973A CA 2893973 A1 CA2893973 A1 CA 2893973A1
- Authority
- CA
- Canada
- Prior art keywords
- mal
- ppi
- iii
- dendrimer
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/002—Dendritic macromolecules
- C08G83/003—Dendrimers
- C08G83/004—After treatment of dendrimers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL401936A PL234888B1 (pl) | 2012-12-06 | 2012-12-06 | Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej |
| PLP-401936 | 2012-12-06 | ||
| PCT/PL2013/000163 WO2014088435A1 (en) | 2012-12-06 | 2013-12-06 | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2893973A1 true CA2893973A1 (en) | 2014-06-12 |
Family
ID=49955472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2893973A Abandoned CA2893973A1 (en) | 2012-12-06 | 2013-12-06 | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9877985B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2928479A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2016501261A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20150093216A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2013356793A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2893973A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL239144A0 (cg-RX-API-DMAC10.html) |
| PL (1) | PL234888B1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2014088435A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL234887B1 (pl) * | 2012-12-06 | 2020-04-30 | Univ Lodzki | Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej |
| PL416636A1 (pl) * | 2016-03-24 | 2017-09-25 | Univ Łódzki | Medyczne zastosowanie dendrymeru polipropylenoiminowego czwartej generacji, opłaszczonego maltotriozą |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090208580A1 (en) | 2005-09-19 | 2009-08-20 | Regents Of The University Of Michigan | Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles |
| US20110177602A1 (en) * | 2007-06-27 | 2011-07-21 | Endress + Hauser Conducts Gesellschaft furMess-und Regeltechnik mbH +Co. KG | Composite Structure |
| PL234887B1 (pl) * | 2012-12-06 | 2020-04-30 | Univ Lodzki | Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej |
-
2012
- 2012-12-06 PL PL401936A patent/PL234888B1/pl unknown
-
2013
- 2013-12-06 CA CA2893973A patent/CA2893973A1/en not_active Abandoned
- 2013-12-06 EP EP13821004.2A patent/EP2928479A1/en not_active Withdrawn
- 2013-12-06 KR KR1020157018094A patent/KR20150093216A/ko not_active Withdrawn
- 2013-12-06 US US14/650,521 patent/US9877985B2/en not_active Expired - Fee Related
- 2013-12-06 JP JP2015546419A patent/JP2016501261A/ja active Pending
- 2013-12-06 AU AU2013356793A patent/AU2013356793A1/en not_active Abandoned
- 2013-12-06 WO PCT/PL2013/000163 patent/WO2014088435A1/en not_active Ceased
-
2015
- 2015-06-02 IL IL239144A patent/IL239144A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150093216A (ko) | 2015-08-17 |
| AU2013356793A1 (en) | 2015-07-23 |
| PL234888B1 (pl) | 2020-04-30 |
| WO2014088435A1 (en) | 2014-06-12 |
| PL401936A1 (pl) | 2014-06-09 |
| US20150306134A1 (en) | 2015-10-29 |
| EP2928479A1 (en) | 2015-10-14 |
| US9877985B2 (en) | 2018-01-30 |
| JP2016501261A (ja) | 2016-01-18 |
| IL239144A0 (en) | 2015-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shang et al. | Platelet-membrane-camouflaged black phosphorus quantum dots enhance anticancer effect mediated by apoptosis and autophagy | |
| Leanza et al. | Direct pharmacological targeting of a mitochondrial ion channel selectively kills tumor cells in vivo | |
| Gutierrez et al. | A new pyridazinone exhibits potent cytotoxicity on human cancer cells via apoptosis and poly-ubiquitinated protein accumulation | |
| Yih et al. | Arsenite induces prominent mitotic arrest via inhibition of G 2 checkpoint activation in CGL-2 cells | |
| Zhou et al. | Aminated fullerene abrogates cancer cell migration by directly targeting myosin heavy chain 9 | |
| Yusuf et al. | Liposomal encapsulation of silver nanoparticles (AgNP) improved nanoparticle uptake and induced redox imbalance to activate caspase-dependent apoptosis | |
| Ren et al. | Mitochondrial rewiring with small-molecule drug-free nanoassemblies unleashes anticancer immunity | |
| Mameri et al. | Oxidative stress as an underlying mechanism of anticancer drugs cytotoxicity on human red blood cells' membrane | |
| Knotigova et al. | Application of advanced microscopic methods to study the interaction of carboxylated fluorescent nanodiamonds with membrane structures in THP-1 cells: activation of inflammasome NLRP3 as the result of lysosome destabilization | |
| Ünsal et al. | The apoptotic effect of garlic (Allium sativum) derived SEVs on different types of cancer cell lines in vitro | |
| US9877985B2 (en) | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-MAL-III | |
| Zaman et al. | DON encapsulated carbon dot–vesicle conjugate in therapeutic intervention of lung adenocarcinoma by dual targeting of CD44 and SLC1A5 | |
| Chen et al. | An organic free radical generator independent on hydrogen peroxide for chemodynamic and immunotherapy in vivo | |
| Gorojod et al. | Nanohydroxyapatite exerts cytotoxic effects and prevents cellular proliferation and migration in glioma cells | |
| US20150320692A1 (en) | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii | |
| US10022395B2 (en) | Application of maltotriose-coated 4th generation poly(propyleneimine) dendrimer PPI-G4-OS-Mal-III | |
| Abdulmalek et al. | Thymoquinone-conjugated liposomes improve cytotoxic and proapoptotic effects against hepatocellular cancer by altering the EGFR/ERK/MEK signaling axis | |
| Zhang et al. | Cancer cell membrane fused liposomal platinum (iv) prodrugs overcome cisplatin resistance in esophageal squamous cell carcinoma chemotherapy | |
| Yerrapragada et al. | Treatment of human cells with the anti-cancer drug cisplatin results in the caspase-dependent release of adduct-containing cell-free DNA | |
| Jiang et al. | Iterative‐Designed Multifunctional Carbon Dots Nanodrug for Celastrol Loading, Targeting Delivery, and Combination Therapy of Kidney Stones | |
| Kuo et al. | Induction of the mitochondria apoptosis pathway by phytohemagglutinin erythroagglutinating in human lung cancer cells | |
| Zuo et al. | A novel immunochemotherapy based on immunogenicity-activated and immunosuppression-reversed biomimetic nanoparticles | |
| Cong et al. | Impacts of cationic lipid–DNA complexes on immune cells and hematopoietic cells in vivo | |
| Yulak et al. | A PLK1 inhibitor, RO3280, suppresses proliferation of SNU-16 gastric cancer cells via apoptosis | |
| Joma | Polyphenolic and polydendritic molecules as modulators of glioblastoma multiforme and its microenvironment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20191206 |